Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease

Gariani, Karim, Ryu, Dongryeol, Menzies, Keir J., Yi, Hyon-Seung, Stein, Sokrates, Zhang, Hongbo, Perino, Alessia, Lemos, Vera, Katsyuba, Elena, Jha, Pooja, Vijgen, Sandrine, Rubbia-Brandt, Laura, Kim, Yong Kyung, Kim, Jung Tae, Kim, Koon Soon, Shong, Minho, Schoonjans, Kristina, Auwerx, Johan·2017·Journal of Hepatology
DOI 10.1016/j.jhep.2016.08.024

Cited by (167)

Items 101–167 of 167

  1. Coffeeberry Activates the CaMKII/CREB/BDNF Pathway, Normalizes Autophagy and Apoptosis Signaling in Nonalcoholic Fatty Liver Rodent Model
    Meng-Chun Lu, I‐Te Lee, Ling‐Zong Hong, Eyal Ben-Arie, Yu-Hsuan Lin, Wei‐Ting Lin, Pei‐Yu Kao, Mei‐Due Yang, Yin‐Ching Chan · 2021 · Nutrients
  2. Excessive exercise elicits poly (ADP-ribose) Polymerase-1 activation and global protein PARylation driving muscle dysfunction and performance impairment
    Bárbara Crisol, Matheus Biscaro Rocha, Beatriz Franco, Ana Paula Morelli, Carlos K. Katashima, J A Scylas, Fernanda S. Carneiro, Renata Rosseto Braga, Rafael S. Brícola, Graciana de Azambuja et al. · 2025 · Molecular Metabolism
  3. The effects of zinc supplementation on the metabolic factors in patients with non-alcoholic fatty liver disease: a randomized, double-blinded, placebo-controlled clinical trial
    Seyed Mohammad Amin Rezaei, Farzaneh Mohammadi, Mohammad Hassan Eftekhari, Fardad Ejtehadi, Haleh Ghaem, Nazanin Mohammadipoor · 2023 · BMC Nutrition
  4. Nicotinamide N-methyltransferase in non-alcoholic fatty liver disease: Mechanistic insights and emerging therapeutic strategies
    Chen-Ying Zhang, Xiaojuan Zhu, Wei-Dong Sun, Shuang-Zhou Bi, Shi-Yan Lai, An-Liu, Jiang-Hua Li · 2025 · Archives of Biochemistry and Biophysics
  5. PARP-1 inhibitor alleviates liver lipid accumulation of atherosclerosis via modulating bile acid metabolism and gut microbes
    Yingkun Sheng, Guibing Meng, Zhirong Zhou, Ruijiao Du, Yuefei Wang, Miaomiao Jiang · 2023 · Molecular Omics
  6. A ribose-functionalized NAD + with versatile activity for ADP-ribosylation
    Elisa N. Stephens, Xiaonan Zhang, Albert T. Lam, Jiawei Li, Hua Pei, Stan G. Louie, Clay C. C. Wang, Yong Zhang · 2023 · Chemical Communications
  7. Detection of significant SNP associated with production and oil quality traits in interspecific oil palm hybrids using RARSeq
    Maider Astorkia, Mónica Hernández, Stéphanie Bocs, Kevin Ponce, Olga León, Shone Morales, Nathalie Quezada, Francisco Orellana, Fahmi Wendra, Zulhermana Sembiring et al. · 2019 · Plant Science
  8. The Many Roles Mitochondria Play in Mammalian Aging
    Caio M.P.F. Batalha, Aníbal Eugênio Vercesi, Nadja Cristhina de Souza-Pinto · 2021 · Antioxidants and Redox Signaling
  9. The past-tense debate
    Steven A. Pinker, Michael T. Ullman · 2002
  10. Resveratrol Inhibits Nucleosome Binding and Catalytic Activity of PARP1
    Д. О. Кошкина, Natalya V. Maluchenko, Anna N. Korovina, Лобанова Ангелина Андреевна, Alexey V. Feofanov, Vasily M. Studitsky · 2024 · Biomolecules
  11. Total ginsenosides and ginsenoside Rb2 delay hepatocyte senescence by regulating NAD+ metabolism and promoting IDO2/QPRT expression
    Guo Chen, Mingxia Wu, Ze-peng Zhang, Jing Li, Jin-jin Chen, Hang Su, Kun Wei, Daqing Zhao, Xiangyan Li, Qingxia Huang · 2025 · Journal of Ginseng Research
  12. GBA3 promotes fatty acid oxidation and alleviates non-alcoholic fatty liver by increasing CPT2 transcription
    Juyi Li, Yingqun Ni, Yuanyuan Zhang, Huaizhen Liu · 2024 · Aging
  13. Bioevaluation of magnetic mesoporous silica rods: cytotoxicity, cell uptake and biodistribution in zebrafish and rodents
    Jan Grzelak, Mariana Teles, Nerea Roher, Alba Grayston, Anna Rosell, Martí Gich, Anna Roig · 2022 · RSC Advances
  14. Hyperpolarized [ 1‐ 13 C ] pyruvate MRSI to detect metabolic changes in liver in a methionine and choline‐deficient diet rat model of fatty liver disease
    Joao Piraquive Agudelo, Yaewon Kim, Shubhangi Agarwal, Renuka Sriram, Robert Bok, John V. Kurhanewicz, Aras N. Mattis, Jacquelyn J. Maher, Cornelius von Morze, Michael A. Ohliger · 2023 · Magnetic Resonance in Medicine
  15. Nampt: a new therapeutic target for modulating NAD+ levels in metabolic, cardiovascular, and neurodegenerative diseases
    Ravikumar Manickam, Sandhya Santhana, Wanling Xuan, Kirpal S. Bisht, Srinivas M. Tipparaju · 2025 · Canadian Journal of Physiology and Pharmacology
  16. The Crucial Role of NAD+ in Mitochondrial Metabolic Regulation
    Kumudesh Mishra, Or Kakhlon · 2025 · Biocell
  17. Roles and therapeutic potential of PARP-1 in neurodegenerative diseases
    Chang Liu, Feifan Lai, Ting Zhang, Kunjun Mao, Haitong Wan, Yu Ting He · 2025 · Biochemical Pharmacology
  18. Adverse Maternal Environment and Postweaning Western Diet Alter Hepatic CD36 Expression and Methylation Concurrently with Nonalcoholic Fatty Liver Disease in Mouse Offspring
    Qi Fu, Paula E. North, Xingrao Ke, Yi‐Wen Huang, Katie A. Fritz, Amber V. Majnik, Robert H. Lane · 2021 · Journal of Nutrition
  19. Relationship between probiotics and obesity: a review of recent research
    Jing ZHANG, Jianfei Mu, XiXi LI, Xin Zhao · 2022 · Food Science and Technology
  20. Biochemical properties of the plasma of rats with the experimentally induced hepatitis after oral administration of sodium diclofenac
    Viktoriya Gryshchenko · 2017 · Regulatory Mechanisms in Biosystems
  21. PARP‑1 in liver diseases: Molecular mechanisms, therapeutic potential and emerging clinical applications (Review)
    Kaipeng Hu, Heng Tian, Shuxing Chen, Yuhan Liu, Ran Wei, Bangjie Chen, Yiwen Jia · 2025 · Molecular Medicine Reports
  22. Elucidating the Therapeutic Utility of Olaparib in Sulfatide-Induced Human Astrocyte Toxicity and Neuroinflammation
    Marianna Mekhaeil, Melissa Jane Conroy, Kumlesh Kumar Dev · 2023 · Journal of Neuroimmune Pharmacology
  23. Influence of phospholipid-containing additives on the functional condition of organs and systems of mice
    Viktoriya Gryshchenko · 2020 · Ukrainian journal of veterinary sciences
  24. The influence of dietary structures composed of different fat globule interfaces on lipid metabolism in mice with a high-fat diet
    Jiaxin Qiu, Yue Pan, Meiyun Li, Jinglong Xu, Lu Liu, Xiaodong Li, Yimeng Geng, Zhixing Zhang, Xuejiao Huang · 2025 · Food Research International
  25. Discovery of PARP1-Sparing Inhibitors for Protein ADP-Ribosylation
    Elisa N. Stephens, Liang‐Chieh Chen, Arshad Jamal Ansari, Kaiyu Shen, Lei Zhang, Steven G. Guillen, Clay C. C. Wang, Yong Zhang · 2024 · ACS Medicinal Chemistry Letters
  26. Need for NAD+: Focus on Striated Muscle Laminopathies
    Déborah Cardoso, Antoine Muchir · 2020 · Cells
  27. CD38 Inhibition Protects Fructose-Induced Toxicity in Primary Hepatocytes
    S.H. Lee, Sung‐E Choi, Seokho Park, Yoonjung Hwang, Youngho Son, YUP Y. KANG · 2023 · Molecules and Cells
  28. Clonorchis sinensis aggravated liver fibrosis by activating PARP-1 signaling to induce parthanatos via DNA damage
    Penglin Bao, Xiaocen Wang, Xu Zhang, Yanhui Yu, Yeting Ma, Haoyang Zhang, Yuru Wang, Xiaolei Liu, Pengtao Gong, Nan Zhang et al. · 2024 · Veterinary Parasitology
  29. Biochemical Targets and Molecular Mechanism of Matrine against Aging
    Kaiyue Sun, Yingzi Zhang, Yingliang Li, Pengyu Yang, Yingting Sun · 2023 · International Journal of Molecular Sciences
  30. Deacetylated PCBP1 licenses PARP1 activity for DNA damage repair
    Yuxin Shu, Jun Zhang, Linmin Zhou, Tingting Feng, Feng Chen, Huangqi Tang, Mengyan Li, Jinqin Qian, Mengzhu Qin, Zixiang Wang et al. · 2026 · Molecular Cell
  31. PARP inhibitors target cellular energy metabolism: Mechanisms of action and clinical implications
    Jiajia Li, Degong Mu, Li Peng Jin, Maozhuo Lan, Wei Wu, Songling Zhang, Yun Dai · 2026 · Translational Oncology
  32. Nutraceutical and dietary measures with potential for preventing/controlling non-alcoholic fatty liver disease and its complications
    Lidianys María Lewis Luján, Mark Frederick McCarty, J.C. Galvez-Ruiz, Sergio Trujillo López, Simon Bernard Iloki Assanga · 2024 · Human Nutrition & Metabolism
  33. Metabolic Activation of PARP as a SARS-CoV-2 Therapeutic Target—Is It a Bait for the Virus or the Best Deal We Could Ever Make with the Virus? Is AMBICA the Potential Cure?
    Prasanth Puthanveetil · 2023 · Biomolecules
  34. Personalized Medicine in Oncology
    Ari M. Vanderwalde · 2022 · MDPI eBooks
  35. The clinically applied PARP inhibitor talazoparib ameliorates imiquimod-induced psoriasis in mice without reducing skin inflammation
    Petra Molnár, Máté Ágoston Demény, Beáta Várkonyi, Zsuzsanna Polgár, Ágnes Pór, Ilona Kovács, Andrea Szegedi, Attila Gábor Szöllősi, Magdolna Szántó · 2025 · Frontiers in Pharmacology
  36. NAD + in fatty liver disease: mechanistic insights and associated targets
    Ya-Xin Guo, Yuting Wang, Shiran Wu, Yong Wang, Xinde Liu · 2025 · Cell Biology and Toxicology
  37. Genetic and Epigenetic Associations of NAFLD: Focus on Clinical Decision Making
    Mayada Metwally, Mohammed Eslam, Jacob George · 2017 · Current Hepatology Reports
  38. ANTI-OBESITY NUTRACEUTICALS: INSIGHTS INTO MECHANISMS OF ACTION AND POTENTIAL USE OF BIOCOMPATIBLE NANOCARRIERS FOR DELIVERY
    DOAA SALAH ELDIN ABDELFATTAH, Mervat A. Fouad, Aliaa Nabil ElMeshad, Mohamed A. El-Nabarawi, Sammar Fathy Elhabal · 2024 · International Journal of Applied Pharmaceutics
  39. Pharmacological Approaches for Modulating Sirtuins
    Alice E. Kane, David A. Sinclair · 2018 · Elsevier eBooks
  40. Naturalne i syntetyczne modulatory aktywności sirtuin
    Magdalena Wiercińska, Danuta Rosołowska‐Huszcz · 2017
  41. Energy metabolism adaptations and gene expression reprogramming in a cellular MAFLD model
    Tianran Zhou, Cagla Cömert, Xiaoyu Zhou, Lin Lin, Lars Bolund, Johan Palmfeldt, Guangdong Tong, Yonglun Luo, Peter Bross · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  42. StarD5 Plays a Critical Role in the Hepatocyte ER Stress Survival Response
    William M. Pandak, Genta Kakiyama, Daniel Rodríguez‐Agudo · 2025 · International Journal of Molecular Sciences
  43. PARPs in liver diseases
    Jiaxin Xia, Xiao Ping Tang, Qihua Zhu, Yizhu Xu · 2025 · npj gut and liver.
  44. Roles and mechanisms of Pueraria lobata radix in metabolic dysfunction-associated steatotic liver disease
    Xu Zhou, Hongmei Xu, Hui Wang, Hairong Zhang, Ying Chen, Jianrong Chen · 2026 · Journal of Ethnopharmacology
  45. Poly(ADP-ribose) polymerase (PARP)-targeted PET imaging in non-oncology application: a pilot study in preclinical models of nonalcoholic steatohepatitis
    Troels E. Jeppesen · 2024 · American Journal of Nuclear Medicine and Molecular Imaging
  46. Inhibition of PARP Activity Attenuated Hepatic Triglyceride Accumulation in Alcoholic Fatty Liver Disease in Mice
    Shishun Huang, Bing Zhang, Yingli Chen, Huan Liu, Yang Liu, Xin Li, Zhiwei Bao, Zhenyuan Song, Zhigang Wang · 2017 · Preprints.org
  47. NAD + Modulation
    Elena Katsyuba, Johan H. Auwerx · 2018 · Elsevier eBooks
  48. A Review on: “Recent Updates on Poly-Adp-Ribosylation (Parylation) in Physiology and Pathology”
    Pritam Paramguru Mahapatra, Manaswini Giri · 2020 · International Journal of Innovative Science and Research Technology (IJISRT)
  49. Eksenatidin 3D 3T3-L1 Adipositleri Üzerindeki Ekspresyon Profilinin Mikrodizin Analizi ile Belirlenmesi
    Meliha Koldemir Gündüz, Güllü Kaymak, Ertan Kanbur, Derya Berikten, Meryem Cansu Şahin, Harun Şener, Azmi Yerlikaya · 2022 · Iğdır Üniversitesi Fen Bilimleri Enstitüsü Dergisi
  50. NAD + depletion and altered mitochondrial function are key to the establishment of placental dysfunction in an inflammatory-driven subclass of preeclampsia
    Fahmida Jahan, Goutham Vasam, Yusmaris Cariaco, Abolfazl Nik-Akhtar, Alex Green, Keir J. Menzies, Shannon A. Bainbridge · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  51. GalNac-modified red blood cell-derived extracellular vesicles protect against liver diseases
    Gengsheng Zhang, Xiaofang Huang, Jie Yang, Jianning Zhang, Yang Ma, Yuanyuan Hu, Siyu Lu, Shuai Li, Zheng Song, Chen Li et al. · 2024 · Research Square
  52. Effect of zinc supplementation on atherogenic risk indices in patients with non-alcoholic fatty liver disease: a randomized, double-blinded, placebo-controlled clinical trial
    Farzaneh Mohammadi, Mohammad Ali Mohsenpour, Seyed Mohammad Amin Rezaei, Mohammad Hasan Eftekhari · 2025 · BMC Nutrition
  53. Therapeutic targeting of neuroinflammation in sphingolipidosis
    Ebru Ada, Volkan Seyrantepe · 2025 · Molecular Immunology
  54. USP25 deficiency suppresses diet-induced obesity via ubiquitination and degradation of PARP1 and Elovl3 downregulation
    Bowen Xie, Junbo Li, Guobin Huang, Yuanyuan Zhao, Dong Chen, Lai Wei, Fangyu Guo, Rodrigo Machado Florentino, Lanuza A.P. Faccioli, Takeshi Kurihara et al. · 2026 · Journal of Lipid Research
  55. Niacin Derivatives in MASLD: Metabolic and Therapeutic Insights
    Marina Idalia Rojo-López, Julia Niño-Narvión, Maria Antentas, Berta Fernández‐Camins, Elizabeth Martínez-Rojo, María Poca, María Antonia Martínez‐Sánchez, Bruno Ramos‐Molina, Joana Rossell, Dı́dac Mauricio et al. · 2026 · Nutrients
  56. Rôle de la PARylation sur l’apparition des troubles cardiovasculaires dans la progéria de Hutchinson-Gilford
    Déborah Cardoso · 2022 · theses.fr (ABES)
  57. Rôle de la kinase ATR dans la progression de la stéatose hépatique non alcoolique
    Maëva Saroul-Aïnama · 2022 · theses.fr (ABES)
  58. Hepatic Sirt2-PARP1-HMGB1 axis promotes exercise-mediated amelioration of MASH in mice
    Shan Li, Wang-Jing Mu, Zi-Ang Zhao, Wan-Qiu Peng, Jieying Zhu, Ruo-Ying Li, Lin-Jing Yan, Yang Li, Hong-Yang Luo, Min Chen et al. · 2026 · Science China Life Sciences
  59. Repositioning of niacin in atherosclerotic cardiovascular disease
    Wenmei Li, Zhongjie Bai, Congying Li, Shasha Lu, Yumei Wang, Dedong Huang, Hongxia Zhang, Jiamin Yuan, Xin Zhen, Yan Liu · 2026 · PharmaNutrition
  60. Mitochondrial homeostasis and aging: Mechanisms, disease associations, and targeted intervention strategies
    Bao-Sheng WANG, Ben ZHOU · 2026 · Shengming kexue
  61. Mitochondrial NAD+ determines the metabolic capacity for liver regeneration
    Panu K. Luukkonen · 2026 · Journal of Hepatology
  62. A Mathematical Model of Hepatitis B Virus‐Liver Cancer Coexistence Dynamics With Immune Response and Treatment
    Paul Chataa, Samuel M. Naandam, Francis Tanam Djankpa · 2026 · Discrete Dynamics in Nature and Society
  63. Exercise elicits mitonuclear protein imbalance and UPRmt in the liver of mice with obesity
    Matheus Biscaro Rocha, Izabela Monteiro de Araújo, Saulo Gabriel do Nascimento Della Coleta, J A Scylas, Sidney F. Peres, Renata Rosseto Braga, Rafael S. Brícola, Fernanda S. Carneiro, Bárbara Crisol, Raul G. da Costa et al. · 2026 · Journal of Physiology and Biochemistry
  64. Targeting the AKT2-NAMPT phosphorylation axis prevents macrophage senescence to enhance bactericidal activity in septic immunosuppression
    Qilan Li, Mei He, Peichi Shi, Xuefeng Li, Zili Xu, Lu Yao, Xinyi Du, Chaoying Song, Chang Li, Lang Jiang et al. · 2026 · International Immunopharmacology
  65. Improvement of steatohepatitis during therapy with olaparib in metastatic BRCA1-mutated breast cancer: A case report suggesting new opportunities of PARP inhibitors
    María Gión, Diego Burgos‐Santamaría, Luís Téllez, Belén Perez‐Mies, Juan Carlos Calvo-Pérez, Pilar Sotoca, Cristina Saavedra, Alfonso Cortés-Salgado, María Férnandez-Abad, Elena López-Miranda et al. · 2026 · npj gut and liver.
  66. BindingDB Entry 50023530: Discovery of PARP1-Sparing Inhibitors for Protein ADP-Ribosylation.
    BindingDB · 2026 · UC San Diego
  67. Hepatoprotective Effect of Nicotinamide Mononucleotide on High‐Fat Diet‐Induced Non‐Alcoholic Fatty Liver Disease in Mice
    Yiwen Zhang, Yafei Wu, Yanhong Wei, Xuan Liu, Xiaocan Lei, Hua Huang, Meixiang Li · 2026 · Food Science & Nutrition